Pharma Stability: Insights, Guidelines, and Expertise
Excipients serve multiple functions in pharmaceutical dosage forms, including bulking, coating, disintegration, and preservation. Their chemical and physical properties can interact with APIs and affect degradation pathways under long-term storage conditions.
Click to read the full article.
Intermediate condition studies are often required when:
Click to read the full article.
According to ICH Q8(R2), CQAs are defined as “a physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality.”
Click to read the full article.
An OOT result is a data point that does not follow the expected trend of a given stability parameter over time but remains within approved specification limits.
Click to read the full article.
As defined by ICH Q1A(R2), stability conditions must replicate real-time storage environments based on the intended market:
Click to read the full article.
According to ICH Q1A(R2), intermediate conditions are required:
Click to read the full article.
A product-specific stability profile is a tailored representation of a drug’s behavior over time under various storage conditions. It captures the trends of critical quality attributes (CQAs), degradation kinetics, and environmental sensitivities specific to that formulation.
Click to read the full article.
As outlined in ICH Q1A(R2), intermediate testing is generally conducted:
Click to read the full article.
The packaging system plays a major role in protecting the drug product from environmental factors such as:
Click to read the full article.
Shelf-life extensions are considered when:
Click to read the full article.
Don’t leave empty-handed. Watch practical GMP scenarios, inspection lessons, deviations, CAPA thinking, and real compliance insights on our YouTube channel. One click now can save you hours later.